Both Neuralstem Inc. (NASDAQ:CUR) and Zealand Pharma A/S (NASDAQ:ZEAL) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuralstem Inc.	N/A	32.21	4.92M	-0.52	0.00
Zealand Pharma A/S	N/A	0.00	N/A	3.00	5.18

Table 1 highlights Neuralstem Inc. and Zealand Pharma A/S’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

	Net Margins	Return on Equity	Return on Assets
Neuralstem Inc.	0.00%	-123.1%	-74.7%
Zealand Pharma A/S	0.00%	0%	0%

Institutional and Insider Ownership

Institutional investors held 16.8% of Neuralstem Inc. shares and 9.28% of Zealand Pharma A/S shares. Insiders held roughly 13.52% of Neuralstem Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Neuralstem Inc.	6.47%	16.4%	0.1%	-58.3%	-66.18%	59.85%
Zealand Pharma A/S	6.55%	7.93%	34.59%	9.24%	-2.23%	33.89%

For the past year Neuralstem Inc. was more bullish than Zealand Pharma A/S.

Summary

Zealand Pharma A/S beats on 5 of the 8 factors Neuralstem Inc.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companyÂ’s stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.